KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Intangibles: 2017-2023

Historic Intangibles for Aquestive Therapeutics (AQST) over the last 7 years, with Dec 2023 value amounting to $1.3 million.

  • Aquestive Therapeutics' Intangibles fell 11.25% to $1.2 million in Q1 2024 from the same period last year, while for Mar 2024 it was $1.2 million, marking a year-over-year decrease of 11.25%. This contributed to the annual value of $1.3 million for FY2023, which is 10.94% down from last year.
  • Aquestive Therapeutics' Intangibles amounted to $1.3 million in FY2023, which was down 10.94% from $1.4 million recorded in FY2022.
  • Aquestive Therapeutics' 5-year Intangibles high stood at $2.9 million for FY2019, and its period low was $51,000 during FY2021.
  • For the 3-year period, Aquestive Therapeutics' Intangibles averaged around $921,333, with its median value being $1.3 million (2023).
  • Its Intangibles has fluctuated over the past 5 years, first crashed by 96.44% in 2020, then surged by 2,713.73% in 2022.
  • Over the past 5 years, Aquestive Therapeutics' Intangibles (Yearly) stood at $2.9 million in 2019, then slumped by 96.44% to $102,000 in 2020, then plummeted by 50.00% to $51,000 in 2021, then surged by 2,713.73% to $1.4 million in 2022, then dropped by 10.94% to $1.3 million in 2023.